Urothelial Carcinoma: Novel Therapies and Strategies to Improve Patient Outcomes

The goal of this activity is to improve the knowledge, confidence, and performance of learners to integrate recent findings into the treatment of patients with urothelial carcinoma.

 

Provided by the National Comprehensive Cancer Network in partnership with Clinical Care Options, LLC

Target Audience

This program is intended for physicians, physician assistants, nurses, pharmacists, and other healthcare providers who care for patients with urothelial carcinoma.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Integrate checkpoint inhibitor therapies into practice to optimize the care of patients with advanced urothelial carcinoma, considering the available evidence, and patient and disease characteristics
  • Incorporate guideline and expert recommendations to optimally manage adverse events associated with the use of immune checkpoint inhibitors 
  • Evaluate biomarkers that accurately predict treatment response and assist in patient selection for personalized therapy
  • Describe the available data and available therapeutic options for maintenance therapy after induction chemotherapy in advanced urothelial carcinoma
  • Plan therapy for patients with urothelial carcinoma and disease progression during or following platinum-containing chemotherapy and/or immune checkpoint inhibitor therapy
  • Discuss ongoing clinical trials investigating targeted systemic therapies and immune checkpoint inhibitor–based combinations for patients across the urothelial carcinoma disease spectrum
Additional information
Supporters: 

Supported by an educational grant from Seattle Genetics & Astellas

Course summary
Available credit: 
  • 1.25 AAPA Category 1 CME credit
  • 1.25 ACPE contact hours
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 ANCC contact hours
  • 1.25 Participation
Course opens: 
08/19/2021
Course expires: 
08/19/2022
Cost:
$0.00

Faculty
Elizabeth Plimack, MD
Fox Chase Cancer Center

Arlene O. Siefker-Radtke, MD
The University of Texas MD Anderson Cancer Center

 

NCCN Medical Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. 

Definitions  

Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

Faculty Disclaimers  

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.

Faculty Disclosures

The faculty listed below have the following relevant financial relationships with ineligible companies to disclose.  All of the relevant financial relationships listed for these individuals have been mitigated.

Elizabeth Plimack, MD
Astellas Pharma US, Inc.: Grant/Research Support
AstraZeneca Pharmaceuticals LP: Scientific Advisor
Bristol-Myers Squibb Company: Grant/Research Support
Genentech, Inc.: Grant/Research Support, Scientific Advisor
Infinity Pharmaceuticals, Inc.: Scientific Advisor 
Merck & Co., Inc.: Grant/Research Support, Scientific Advisor
Pfizer Inc.: Scientific Advisor 
Seagen (formerly Seattle Genetics, Inc.): Scientific Advisor 

Arlene O. Siefker-Radtke, MD
AstraZeneca Pharmaceuticals LP: Scientific Advisor
Basilea Pharmaceutica AG: Grant/Research Support, Scientific Advisor
Bristol-Myers Squibb Company: Grant/Research Support, Scientific Advisor
Genentech, Inc.: Scientific Advisor
IDEAYA Biosciences: Scientific Advisor
Immunomedics, Inc.: Scientific Advisor
Janssen Pharmaceutica Products, LP: Grant/Research Support, Scientific Advisor, fees for non-CME/CE services
Merck & Co., Inc.: Grant/Research Support, Scientific Advisor
Mirati Therapeutics, Inc.: Scientific Advisor
Nektar Therapeutics: Grant/Research Support, Scientific Advisor
Seagen (formerly Seattle Genetics, Inc.): Scientific Advisor
Taiho Pharmaceuticals Co., Ltd.: Scientific Advisor

NCCN/CCO Staff Disclosures

None of the planners for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. National Comprehensive Cancer Network® (NCCN®) and Clinical Care Options, LLC, do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of NCCN and Clinical Care Options, LLC. Please refer to the official prescribing information for each product for discussion of approved indication, contraindications, and warnings.

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians
NCCN designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
NCCN designates this educational activity for a maximum of 1.25 contact hours.

Pharmacists
NCCN designates this application-based continuing education activity for 1.25 contact hours (0.125 CEUs) of continuing education credit. UAN: JA4008196-0000-21-096-H01-P

Physician Assistants
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.25 AAPA Category 1 CME credits. Approval is valid until August 19, 2022. PAs should only claim credit commensurate with the extent of their participation.

Available Credit

  • 1.25 AAPA Category 1 CME credit
  • 1.25 ACPE contact hours
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 ANCC contact hours
  • 1.25 Participation

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
    • One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
    • Internet Explorer is no longer supported
  • Adobe Reader or other PDF reader software for certificate viewing/printing